Current progress of mesenchymal stem cell membrane-camouflaged nanoparticles for targeted therapy
Open accessAbstract
Nanodrug delivery systems have been widely used in disease treatment. However, weak drug targeting, easy to be cleared by the immune system, and low biocompatibility are great obstacles for drug delivery. As an important part of cell information transmission and behavior regulation, cell membrane can be used as drug coating material which represents a promising strategy and can overcome these limitations. Mesenchymal stem cell (MSC) membrane, as a new carrier, has the characteristics of active targeting and immune escape of MSC, and has broad application potential in tumor treatment, inflammatory disease, tissue regeneration and other fields. Here, we review recent progress on the use of MSC membrane-coated nanoparticles for therapy and drug delivery, aiming to provide guidance for the design and clinical application of membrane carrier in the future.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The MSC membrane can prolong the circulation of nucleic acid drugs by protecting them from degradation by nucleases.
“It can prolong the circulation of nucleic acid drugs by protecting them from the degradation of nucleases, representing a promising drug delivery platform [371].”
From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [371]
Cites
Inflammation, metaflammation and immunometabolic disorders
Hotamisligil, G. S. (2017) · Nature · doi:10.1038/nature21363 · Cited by 2,570 · see citing works
Frenette, P. S., Pinho, S., Lucas, D., & Scheiermann, C. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095919 · Cited by 462 · see citing works
Mesenchymal stem/stromal cells in cancer therapy
Lan, T., Luo, M., & Wei, X. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01208-w · Cited by 374 · see citing works
Phototheranostics: Active Targeting of Orthotopic Glioma Using Biomimetic Proteolipid Nanoparticles
Jia, Y., Wang, X., Hu, D., Wang, P., Liu, Q., Zhang, X., Jiang, J., Liu, X., Sheng, Z., Liu, B., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b06556 · Cited by 211 · see citing works
Unveiling the <i>in Vivo</i> Protein Corona of Circulating Leukocyte-like Carriers
Corbo, C., Molinaro, R., Taraballi, F., Toledano Furman, N. E., Hartman, K. A., Sherman, M. B., De Rosa, E., Kirui, D. K., Salvatore, F., & Tasciotti, E. (2017) · ACS Nano · doi:10.1021/acsnano.7b00376 · Cited by 155 · see citing works
Babajani, A., Soltani, P., Jamshidi, E., Farjoo, M. H., & Niknejad, H. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00748 · Cited by 99 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Pan, X., Gao, T., & Wang, B. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01520-9 · Cited by 2 · see citing works
“It can prolong the circulation of nucleic acid drugs by protecting them from the degradation of nucleases, representing a promising drug delivery platform [371].”
- Authors
- Fan, L., Wei, A., Gao, Z., & Mu, X.
- Affiliations
- Jilin University (CN)
- Corresponding author
- Mu, Xupeng
- ORCID
- Venue
- Biomedicine & Pharmacotherapy
- Publisher
- Elsevier BV
- Published
- 2023-05
- Volume
- 161
- Pages
- 114451
- ISSN
- 0753-3322 (ISSN-L)
- OpenAlex
- W4322762433
- Cited by
- 57
- References
- 6
- Citations by year
- 2026: 16 · 2025: 17 · 2024: 19 · 2023: 5
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomedicine & Pharmacotherapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Jilin Provincial Natural Science Foundation (20200201558JC)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- membrane-coated nanoparticles, nanoparticle drug delivery, active targeting, immune evasion, cancer therapy, inflammatory diseases, tissue regeneration, biocompatibility
- MeSH terms
- Cell Membrane, Excipients, Membranes, Drug Delivery Systems, Nanoparticles, Mesenchymal Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
